BPC-157
10 mg vial, 60 capsules
Credible retatrutide results come from randomised, placebo controlled trials, and nowhere else. Take the 12 mg arm of the phase 2 obesity study as an example. Its average loss stood at 17.5% after 24 weeks, reached 24.2% by week 48, and the phase 3 programme later reported 28.3% at 80 weeks. This AminoLab guide traces how those numbers accumulated, study by study and dose by dose, so a research group can see exactly what the published record does and does not show.
Online before and after pictures and personal anecdotes are everywhere, and almost none of them carry evidential weight. Retatrutide has no approval in any country, which means anything used outside a trial came from an unverified source. The TGA has already flagged products sold in Australia as retatrutide that turned out to contain none. A photograph says nothing about what the vial held.
A properly run trial does. Hundreds or thousands of participants receive a defined dose or a placebo and are measured at set intervals, and no other retatrutide review is worth your time. Everything below summarises those trials. None of it predicts an individual outcome, and none of it is a recommendation to use the compound.
Jastreboff and co-authors published the phase 2 obesity trial in the New England Journal of Medicine in 2023. It enrolled 338 adults living with obesity, or with overweight plus a related condition, and gave them retatrutide or placebo once a week for 48 weeks. Mean change in body weight from the starting point was as follows.
| Weekly dose arm | Participants down 15% or more at week 48 | Mean loss, week 48 | Mean loss, week 24 |
|---|---|---|---|
| Placebo | 2% | 2.1% | 1.6% |
| 1 mg | not reported here | 8.7% | 7.2% |
| 4 mg (combined) | 60% | 17.1% | 12.9% |
| 8 mg (combined) | 75% | 22.8% | 17.3% |
| 12 mg | 83% | 24.2% | 17.5% |
Notice what happened in the second half of the study. Higher dose arms were still trending downward between weeks 24 and 48, and the authors observed that no plateau had appeared by the final visit. In the 12 mg arm, not one participant lost less than 5%, 93% passed the 10% mark and 83% passed 15%.
The answer to how long does retatrutide take to work changes with the endpoint. Across the trials, three distinct timelines emerge.
There is also the matter of how long does it take for retatrutide to suppress appetite, and here the honest answer is that nobody knows. No published trial reported appetite as its own early endpoint, so a trustworthy number does not exist. GLP-1 receptor activation generally curbs appetite within a short time, but in these studies the starting doses were kept small on purpose and raised step by step. Any precise count of days you come across is not drawn from the published record.
Phase 3 is far bigger and runs considerably longer than phase 2. Headline figures released so far are set out here.
| Study | Weeks of follow up | Headline outcome | Enrolled population |
|---|---|---|---|
| TRIUMPH-1 | 80 weeks | Weight down 28.3% on 12 mg, 25.9% on 9 mg and 19.0% on 4 mg | 2,339 adults without diabetes, living with obesity or overweight |
| TRIUMPH-1 extension | 104 weeks | 30.3% on 12 mg | 532 people whose BMI was 35 or more |
| TRIUMPH-4 | 68 weeks | 12 mg arm 28.7%, placebo arm 2.1% | 445 adults with knee osteoarthritis and obesity |
| TRANSCEND-T2D-1 | 40 weeks | Weight 11.5% to 16.8% lower, HbA1c 1.7 to 2.0 points lower | 537 adults living with type 2 diabetes |
| TRIUMPH-2 and TRIUMPH-3 | 80 weeks | Near 21% and 23% on the highest doses | Obesity plus type 2 diabetes, or obesity plus cardiovascular disease |
Most of these numbers are topline results announced by Lilly, while TRANSCEND-T2D-1 has appeared in full in The Lancet (2026). We would cite the 80 week TRIUMPH-1 figure ahead of the 30.3%. That longer result describes only a subgroup who started with a higher BMI and completed the main study, so leading with it overstates the picture.
Sanyal and co-authors reported a liver fat substudy in Nature Medicine in 2024, tracking 98 obesity trial participants who had fatty liver disease. At week 48, liver fat had fallen in relative terms by 51.3% on 1 mg, 59.0% on 4 mg, 81.7% on 8 mg and 86.0% on 12 mg, against a placebo change of 4.6%. Normal liver fat (under 5%) had been reached by 86% of the 12 mg group as early as week 24, a level no placebo participant achieved. Researchers believe the glucagon receptor arm contributes most here.
For type 2 diabetes, Rosenstock and co-authors (The Lancet, 2023) found HbA1c fell between 1.30% and 2.02% at week 24 on doses of 4 mg or more, with placebo essentially flat, and body weight dropped by up to roughly 16.9% at week 36 with no obvious plateau. TRANSCEND-T2D-1 in phase 3 landed in a similar band. Across incretin drugs, people with diabetes reliably lose less weight than those without it, which accounts for the lower TRIUMPH-2 figures.
For researchers, these published outcomes set the benchmark for a positive control and point to which receptor contributions are worth teasing apart. Read how retatrutide works for the balance across its three receptors, while dose by dose tolerability is covered in the trial side effect data.
Lab handling is straightforward. Freeze-dried powder goes back into solution with bacteriostatic water for peptides, and volumes are measured using U-100 insulin syringes. Enter your vial size into the retatrutide reconstitution calculator to see how much compound each unit holds, and browse the research library for the PubMed references used on this page.
Once you know the benchmark you are aiming for, the decision that remains is how much material to buy. The 10 mg retatrutide vial covers pilot work or one dose response experiment. New customers frequently go for the Retatrutide Starter Kit. For a dual agonist comparator, choose tirzepatide in a 2 mg vial. Everything ships from Australian stock, so order online and match the lot to its certificate before work begins.
AminoLab supplies retatrutide only for laboratory research by adults 18 and over, never for human or veterinary use. Every retatrutide result quoted on this page is a published finding, offered as context for research and nothing more.
In the phase 2 obesity study, the 12 mg arm had already lost 17.5% by week 24 and reached 24.2% by week 48, still without a plateau. HbA1c changes in type 2 diabetes were assessed at week 24, and most of the drop in liver fat was visible by then too. These are group averages, not forecasts for any one person.
The trials publish totals at set visits, not weekly figures. As a rough guide, the 12 mg phase 2 arm dropped 17.5% in weeks 1 to 24, then a further 6.7 points in weeks 25 to 48, meaning the pace eased over time. It was never linear, and individuals spread widely either side of the mean.
The TRIUMPH-1 extension reported 30.3% on 12 mg after 104 weeks, the highest average so far, but its participants began with a BMI of 35 or higher and had completed the main trial. A fairer figure is the main TRIUMPH-1 result Lilly announced in May 2026, an average of 28.3% on 12 mg after 80 weeks.
They cannot. Retatrutide is unapproved everywhere, so any photo online involves a product nobody has verified, and the TGA has found items sold in Australia under the retatrutide name that actually contained another drug. Pictures also hide the dose, duration and diet involved. Only randomised trials with a placebo arm give reliable retatrutide results.
AminoLab sells it online for laboratory research only, and stock in Australia covers freeze-dried fills of 10, 20 or 30 mg, a 10 mg pen and a starter kit. An independent laboratory confirms identity by mass spectrometry and measures purity by HPLC for each lot. Pick the size your study needs, then read that lot's certificate in the COA library before you check out.
10 mg vial, 60 capsules
50 mg vial, 100 mg vial
10 mg vial
3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe
Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.
Leave